Most of the meta-analyses focused on the effect of EGFR-TKIs4,29–31 have been published; some studies that determined the toxicity mostly focused on the fatal AEs such as treatment-related mortality,32 interstitial lung disease,9 skin rash,33 and gastrointestinal toxicities.34 To the best of our knowledge, this is the first meta-analysis to demonstrate a significantly decreased risk of ≥grade 3 neutropenia and leukopenia as a result of erlotinb-related treatment compared with CT. Here, EGFR is linked to neutropenia.